ProfileOfResearchers

Identificadas 23

21

TÃTULO: Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up Full Text
AUTORES: Wirth, M; Tyrrell, C; Delaere, K; Sanchez Chapado, M; Ramon, J; Wallace, DMA; Hetherington, J; Pina, F; Heyns, CF; Navani, S; Armstrong, J;
PUBLICAÇÃO: 2007, FONTE: PROSTATE CANCER AND PROSTATIC DISEASES, VOLUME: 10, NÚMERO: 1

INDEXADO EM:

Scopus

WOS

22

TÃTULO: Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme Full Text
AUTORES: Wirth, M; Tyrrell, C; Delaere, K; Sanchez Chapado, M; Ramon, J; Wallace, DMA; Hetherington, J; Pina, F; Heyns, C; Borchers, T; Morris, T; Armstrong, J;
PUBLICAÇÃO: 2005, FONTE: PROSTATE CANCER AND PROSTATIC DISEASES, VOLUME: 8, NÚMERO: 2

INDEXADO EM:

Scopus

WOS

23

TÃTULO: Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression Full Text
AUTORES: Wirth, M; Tyrrell, C; Wallace, M; Delaere, KP; Sanchez Chapado, M; Ramon, J; Hetherington, J; Pina, F; Heynes, CF; Borchers, TM; Morris, T; Stone, A;
PUBLICAÇÃO: 2001, FONTE: UROLOGY, VOLUME: 58, NÚMERO: 2

INDEXADO EM:

Scopus

WOS

Página 3 de 3. Total de resultados: 23.

<<
<
1
2
3
>
>>

Um espaço para investigadores e suas Instituições

Links Úteis

Ajuda

© 2024 CRACS & Inesc TEC - All Rights Reserved Política de Privacidade | Terms of Service